

SelectMDx improves prostate biopsy decision-making

December 2018—MDxHealth announced that the journal *Urology Practice* (Shore N, et al. Epub ahead of print Nov. 5, 2018) has published a study demonstrating the clinical utility of SelectMDx, a noninvasive liquid biopsy test to identify patients at increased risk of aggressive prostate cancer, in guiding initial prostate biopsy decision-making.

The study involved five U.S. community urology practices that sequentially enrolled 418 patients who received a SelectMDx test while undergoing evaluation for initial prostate biopsy. The investigators determined biopsy and prostate cancer detection rates in SelectMDx-positive (high-grade prostate cancer detected) versus SelectMDx-negative patients (those at lower risk for aggressive prostate cancer). SelectMDx was shown to have a significant impact on initial prostate biopsy decision-making. SelectMDx-positive men, who are more likely to benefit from treatment, were five times more likely to receive a biopsy than SelectMDx-negative men. In the subset of patients biopsied within three months of receiving test results, high-grade cancers were discovered only in the SelectMDx-positive men, with none of the SelectMDx-negative patients biopsied within three months of testing being diagnosed with a clinically significant disease.

[MDxHealth](#), 949-812-6979